Long acting GLP-1 receptor agonist (injectable)
Bofanglutide (GZR18) 4 mg injection once weekly
BOFANG_SC_4MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.00 (0.20 to 103) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.77 (0.07 to 84.84) | 0.38 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.73 (0.07 to 74.43) | 0.37 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.10 (0.15 to 13.05) | 0.67 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.43 (0.00 to 30.18) | 0.75 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.08 (0.14 to 12.63) | 0.60 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.71 (0.04 to 11.31) | 0.51 |